Illumina expands Billion Cell Atlas program with new AI drug developers

About this update from Illumina, Inc.

Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO , July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics. -->

View stock analysis, news, and events for Illumina, Inc.